Hemington Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Hemington Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$0	Buy	+24	New	+$422	﹤0.01%	1720

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Hemington Wealth Management's TEVA Position: Q3 2025 in Review

Hemington Wealth Management opened a new position in Teva Pharmaceuticals (TEVA) in Q3 2025: 24 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1720 among its holdings.

550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

Hemington Wealth Management held 24 shares of Teva Pharmaceuticals worth $0 as of Q3 2025.
Teva Pharmaceuticals was a new Hemington Wealth Management position in Q3 2025.
Teva Pharmaceuticals made up ﹤0.01% of Hemington Wealth Management's portfolio in Q3 2025, its #1720 holding.
550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Hemington Wealth Management's 13F filing for Q3 2025, filed 24 Oct 2025.